These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Concise review of lipidomics in nonalcoholic fatty liver disease. Béland-Bonenfant S; Rouland A; Petit JM; Vergès B Diabetes Metab; 2023 May; 49(3):101432. PubMed ID: 36781065 [TBL] [Abstract][Full Text] [Related]
5. Insights into the roles and pathomechanisms of ceramide and sphigosine-1-phosphate in nonalcoholic fatty liver disease. Zhu C; Huai Q; Zhang X; Dai H; Li X; Wang H Int J Biol Sci; 2023; 19(1):311-330. PubMed ID: 36594091 [TBL] [Abstract][Full Text] [Related]
6. Lipidomics in pathogenesis, progression and treatment of nonalcoholic steatohepatitis (NASH): Recent advances. Musso G; Saba F; Cassader M; Gambino R Prog Lipid Res; 2023 Jul; 91():101238. PubMed ID: 37244504 [TBL] [Abstract][Full Text] [Related]
8. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH. Pierantonelli I; Svegliati-Baroni G Transplantation; 2019 Jan; 103(1):e1-e13. PubMed ID: 30300287 [TBL] [Abstract][Full Text] [Related]
9. Adipose tissue insulin resistance and lipidome alterations as the characterizing factors of non-alcoholic steatohepatitis. Guerra S; Mocciaro G; Gastaldelli A Eur J Clin Invest; 2022 Mar; 52(3):e13695. PubMed ID: 34695228 [TBL] [Abstract][Full Text] [Related]
10. Coordinated changes of gut microbiome and lipidome differentiates nonalcoholic steatohepatitis (NASH) from isolated steatosis. Qian M; Hu H; Yao Y; Zhao D; Wang S; Pan C; Duan X; Gao Y; Liu J; Zhang Y; Yang S; Qi LW; Wang L Liver Int; 2020 Mar; 40(3):622-637. PubMed ID: 31782595 [TBL] [Abstract][Full Text] [Related]
11. Nonalcoholic fatty liver disease stratification by liver lipidomics. Vvedenskaya O; Rose TD; Knittelfelder O; Palladini A; Wodke JAH; Schuhmann K; Ackerman JM; Wang Y; Has C; Brosch M; Thangapandi VR; Buch S; Züllig T; Hartler J; Köfeler HC; Röcken C; Coskun Ü; Klipp E; von Schoenfels W; Gross J; Schafmayer C; Hampe J; Pauling JK; Shevchenko A J Lipid Res; 2021; 62():100104. PubMed ID: 34384788 [TBL] [Abstract][Full Text] [Related]
12. Stable Isotope-Labeled Lipidomics to Unravel the Heterogeneous Development Lipotoxicity. Shih LM; Tang HY; Lynn KS; Huang CY; Ho HY; Cheng ML Molecules; 2018 Nov; 23(11):. PubMed ID: 30400243 [TBL] [Abstract][Full Text] [Related]
13. Non-Alcoholic Fatty Liver Disease. Engin A Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211 [TBL] [Abstract][Full Text] [Related]
15. Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease. Arab JP; Arrese M; Trauner M Annu Rev Pathol; 2018 Jan; 13():321-350. PubMed ID: 29414249 [TBL] [Abstract][Full Text] [Related]
16. Lipid mediators of liver injury in nonalcoholic fatty liver disease. Liangpunsakul S; Chalasani N Am J Physiol Gastrointest Liver Physiol; 2019 Jan; 316(1):G75-G81. PubMed ID: 30383414 [TBL] [Abstract][Full Text] [Related]
17. Roles of Ceramides in Non-Alcoholic Fatty Liver Disease. Hajduch E; Lachkar F; Ferré P; Foufelle F J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33669443 [TBL] [Abstract][Full Text] [Related]
19. Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. Lee C; Kim J; Jung Y Cells; 2019 Oct; 8(10):. PubMed ID: 31619023 [TBL] [Abstract][Full Text] [Related]
20. Discovering a critical transition state from nonalcoholic hepatosteatosis to nonalcoholic steatohepatitis by lipidomics and dynamical network biomarkers. Sa R; Zhang W; Ge J; Wei X; Zhou Y; Landzberg DR; Wang Z; Han X; Chen L; Yin H J Mol Cell Biol; 2016 Jun; 8(3):195-206. PubMed ID: 26993042 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]